Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
1821 articles
October 202624
Mastectomy and sentinel lymph node biopsy in a patient with left-sided breast cancer and Poland syndrome.
An elderly woman with left-sided Poland syndrome presented with breast cancer detected during routine imaging for malignant melanoma.
Paraneoplastic dermatomyositis preceding detection of metastatic oesophageal squamous cell carcinoma after prolonged remission following pembrolizumab therapy.
A man in his late fifties with a history of treated oesophageal squamous cell carcinoma developed severe dermatomyositis after six years of remission.
Malignant phyllodes tumour with spinal metastasis presenting as cauda equina syndrome.
A female in her early 50s with a history of borderline phyllodes tumour underwent right mastectomy and adjuvant radiotherapy.
First-trimester pregnancy-associated breast cancer managed without pregnancy termination: a report with long-term follow-up.
A patient diagnosed with breast cancer in the first trimester opted to continue her pregnancy rather than terminate it. She underwent total mastectomy and axillary lymph node dissection, with chemotherapy initiated…
Presentation and management of tislelizumab induced toxic optic neuropathy.
A woman with metastatic lung adenocarcinoma developed painless, progressive bilateral visual blurring after receiving second-line treatment with gemcitabine, carboplatin, and tislelizumab.
Primary tongue leiomyosarcoma.
A male patient in his mid 50s presented with a non-healing ulcer on the right lateral border of the tongue, accompanied by impaired tongue movement.
Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).
This phase II randomized controlled trial evaluated the efficacy and safety of toripalimab consolidation after chemoradiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
This phase 3 randomized trial evaluated the efficacy of felzartamab combined with lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone in Chinese patients with relapsed or refractory multiple myeloma.
Low-Dose Cytarabine Plus G-CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study.
This multicenter randomized controlled trial analyzed the efficacy and safety of low-dose chemotherapy (LDC) versus standard-dose chemotherapy (SDC) in 221 children with M2 acute myeloid leukemia.
Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial.
This phase I trial evaluated the safety and preliminary efficacy of a carbon nanoparticle-Fe (II) complex (CNSI-Fe) in 19 patients with refractory solid tumors.
Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia.
This meta-analysis examined the population pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in patients with essential thrombocythemia (ET).
A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.
This Phase I multicenter study evaluated PF-07062119, an anti-GUCY2C/anti-CD3 bispecific antibody, in 79 patients with advanced gastrointestinal cancers.
Clinical Trial Protocol for LPS-Boost: Intensified [ 177 Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
This multicenter, open-label phase 2 trial investigates an intensified treatment schedule of [177Lu]Lu-PSMA-617 for 45 patients with metastatic castration-resistant prostate cancer (mCRPC) and low PSMA expression.
Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
The RESIST-PC Phase 2 trial assessed dosimetry of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. A total of 48 patients were analyzed, receiving either 6.0 or 7.4 GBq per cycle.
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
The OPTIMAL-PSMA study is a Phase 2, open-label, randomized controlled trial evaluating the safety and efficacy of a dose-intensified regimen of [177Lu]Lu-PSMA-597 versus standard dosing in 120 patients with metastatic…
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in Patients with Advanced Hepatocellular Carcinoma.
This Phase I open-label trial evaluated the safety and preliminary efficacy of CT0180, a GPC3-targeted TCR fusion construct, in patients with advanced hepatocellular carcinoma (HCC) who had progressed on standard…
Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial.
This randomized controlled trial evaluated the Prostate cancer Radiation Therapy Outcomes Score (PORTOS) in predicting radiotherapy benefit in 765 patients with early-stage breast cancer.
The Effectiveness of Incentives on Cancer Screening among Indigenous Populations: Systematic Review.
This systematic review assessed the effectiveness of various incentives on cancer screening participation among Indigenous populations.
First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.
This first-in-human, open-label, single-arm Phase I study evaluated the safety and pharmacokinetics of 211At-meta-astatobenzylguanidine (211At-MABG) in 10 patients with unresectable or metastatic pheochromocytomas or…
Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.
This single-arm, multicenter, phase I/II trial evaluated long-term outcomes of third-generation anti-CD30 CAR T-cell therapy in 44 patients with relapsed/refractory CD30+ lymphoma.
Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).
The TRIDENT analysis, a post hoc study of the POSEIDON trial, utilized machine learning to identify patients with metastatic non-small cell lung cancer (NSCLC) who may benefit from adding tremelimumab to durvalumab and…
Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated with Clinical Activity.
This phase II multicenter trial evaluated the efficacy of tisotumab vedotin (TV) in patients with recurrent or metastatic cervical cancer (r/mCC).
Nonarmored GCC-Targeting CAR T-cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer.
This phase I clinical trial evaluated the safety and preliminary efficacy of nonarmored GCC-targeted CAR T-cell therapy in 24 heavily pretreated metastatic colorectal cancer patients.
Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.
This phase III randomized controlled trial investigated the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) in 466 patients with high-risk early triple-negative breast cancer (TNBC) receiving…
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.